Novel biomarkers for subtle myocardial involvement in type I diabetes mellitus
| Autor: | Mona S Kamel, Yasser Sedky, Mona Hafez, Sahar A. Sharaf, Antoine F AbdelMassih, Sonia A. El-Saiedi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Type 1 diabetes
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Type i diabetes mellitus Diastole biomarkers Original Articles medicine.disease Brain natriuretic peptide brain natriuretic peptide Doppler imaging Diabetic cardiomyopathy Internal medicine Troponin I medicine Cardiology Biomarker (medicine) plasma cardiotrophin left ventricular dysfunction Cardiology and Cardiovascular Medicine business type 1 diabetes mellitus |
| Zdroj: | Cardiovascular Endocrinology & Metabolism |
| ISSN: | 2574-0954 |
| Popis: | Background Evaluation of certain biomarkers could be used to predict left ventricular (LV) and right ventricular (RV) function impairment in children with type 1 diabetes mellitus. The aim of this study was to determine the best cardiac biomarker for prediction of diabetic cardiomyopathy. Methodology This study was designed as case-control study. A total of 55 children with type 1 diabetes mellitus (group/G1) and 55 healthy controls (G2) were subjected to echocardiography including 3D-Speckle Tracking Echocardiography and tissue Doppler imaging for assessment of RV and LV systolic and diastolic functions. As well as HbA1c, troponin I, brain natriuretic peptide (BNP), plasma cardiotrophin (CT-1), activin-A, transforming growth factor-β, and human insulin-like growth factor binding protein-7 (IGFBP-7) measurements. Results Diabetic patients showed RV and LV systo-diastolic dysfunction compared to controls, the best predictor of LV systolic dysfunction was CT-1 (sensitivity: 69%, while IGFBP-7 was found to be the best predictor of RV systolic dysfunction (sensitivity: 63%). BNP was found to the best predictor of diastolic RV and LV dysfunction (sensitivity: 82% for both). Conclusion CT-1 has proven to be a diagnostic superiority in LV systolic dysfunction whilst BNP continues to prove every day through our study and through many others that it is the chief marker of diastolic dysfunction and HFpEF. This potential accuracy and the increasing availability of BNP in the outpatient setting make it clear that it should be used as a screening test for diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|